# Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus

> **NCT03350035** · PHASE2 · COMPLETED · sponsor: **Marinus Pharmaceuticals** · enrollment: 17 (actual)

## Conditions studied

- Status Epilepticus
- Convulsive Status EPILEPTICUS
- Non Convulsive Status Epilepticus
- Epilepsy

## Interventions

- **DRUG:** IV Ganaxolone active
- **DRUG:** IV Placebo, non-active

## Key facts

- **NCT ID:** NCT03350035
- **Lead sponsor:** Marinus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-19
- **Primary completion:** 2019-09-18
- **Final completion:** 2019-09-18
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03350035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03350035, "Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03350035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*